Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ATAZANAVIR SULFATE

All products: general benefit

Other products in the same Health Canada class (J05A, J05AE) — coverage varies; not interchangeable

  • Darunavir (Prezista): general benefit, Not a benefit
  • Fosamprenavir (Telzir): general benefit
  • Nelfinavir (Viracept): general benefit
  • Ritonavir (Norvir): general benefit
  • Nirmatrelvir + ritonavir (Paxlovid): limited Use 673, 674, 675
  • Abacavir + lamivudine + zidovudine (Trizivir): general benefit

48 more in the class list below

Reyataz · DIN 02248611 · 200mg · capsule

General benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-30 — choose a marketed DIN from the same-category list.Discontinued 2026-07-30 · checked 2026-09-20
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-30 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2026-07-30 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Reyataz · DIN 02248611 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 2004-11-04 Health Canada: Cancelled post market since 2026-07-30 · brand REYATAZ · ATC J05AE08 ATAZANAVIR · form Capsule · route Oral · ingredients ATAZANAVIR (ATAZANAVIR SULFATE) 200 MG · company Bristol-myers squibb canada · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $2.8552 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72967 · Verify on the e-Formulary ↗ (DIN 02248611)

Source record
DIN 02248611: Reyataz Raw flags: sec3=Y Item: 081800081; group id 64; item number 0127; lccId None; manufacturer id BQU Source form: Cap; strength: 200mg Recorded listing: General benefit Source prices (unrounded): $11.7633; ministry $2.8552 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248611 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72967
Interchangeable products
Jamp Atazanavir · DIN 02513110 · $2.8552 Mylan-Atazanavir · DIN 02456885 · $2.8552 Teva-Atazanavir · DIN 02443813 · $2.8552
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2026-07-30 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:18 Antivirals) and how they are covered

Matched class: 08:18 Antivirals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABACAVIR & LAMIVUDINE & ZIDOVUDINE, ABACAVIR SULFATE, ABACAVIR SULFATE & LAMIVUDINE, BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE, CABOTEGRAVIR, CABOTEGRAVIR & RILPIVIRINE, COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, DARUNAVIR & COBICISTAT, DARUNAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, DELAVIRDINE MESYLATE, DOLUTEGRAVIR, DOLUTEGRAVIR & ABACAVIR & LAMIVUDINE, DOLUTEGRAVIR & RILPIVIRINE, DOLUTEGRAVIR SODIUM/LAMIVUDINE, DORAVIRINE, DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE, ELVITEGRAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR ALAFENAMIDE HEMIFUMARATE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR DISOPROXIL, EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, ETRAVIRINE, FOSAMPRENAVIR CALCIUM, GANCICLOVIR SODIUM, LAMIVUDINE & ZIDOVUDINE, LOPINAVIR & RITONAVIR, MARAVIROC, NELFINAVIR MESYLATE, RALTEGRAVIR POTASSIUM, RILPIVIRINE HYDROCHLORIDE, RITONAVIR Some products covered without a code (check the product listing): ACYCLOVIR, DARUNAVIR, EFAVIRENZ, LAMIVUDINE, NEVIRAPINE, VALACYCLOVIR 08:18 Antivirals

DARUNAVIR

· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 600mg, 800mg · Tab

FOSAMPRENAVIR CALCIUM

· 2 products · General benefit · strengths: 50mg/mL, 700mg · Oral Susp, Tab

NELFINAVIR MESYLATE

· 2 products · General benefit · strengths: 250mg, 625mg · Tab

RITONAVIR

· 2 products · General benefit · strengths: 100mg · Tab

NIRMATRELVIR & RITONAVIR

· 2 products · Limited Use, codes 673, 674, 675 · strengths: 150mg & 100mg · Tab-20 Pk, Tab-30 Pk

ABACAVIR & LAMIVUDINE & ZIDOVUDINE

· 2 products · General benefit · strengths: 300mg & 150mg & 300mg · Tab

ABACAVIR SULFATE

· 4 products · General benefit · strengths: 20mg/mL, 300mg · O/L, Tab

ABACAVIR SULFATE & LAMIVUDINE

· 7 products · General benefit · strengths: 600mg & 300mg · Tab

ACYCLOVIR

· 15 products · Listed, not a benefit (2), General benefit (13) · strengths: 200mg, 400mg, 800mg · Tab

BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE

· 1 products · General benefit · strengths: 50mg & 200mg & 25mg · Tab

CABOTEGRAVIR

· 3 products · General benefit · strengths: 200mg/mL, 30mg · Inj Sol-ER Susp 3mL Vial Kit Pk, Tab

CABOTEGRAVIR & RILPIVIRINE

· 2 products · General benefit · strengths: 200mg/mL & 300mg/mL · Inj Sol-2mL Kit, Inj Sol-3mL Kit Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:18 and 42 more
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: human immunodeficiency virus-1
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE, DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE · General benefit 1 INDICATIONS BIKTARVY (bictegravir/emtricitabine/tenofovir alafenamide) is indicated as a complete regimen for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults and pediatric patients weighing ≥ 25 kg with no known substitution associated with resistance to bictegravir or tenofovir. 1.1 Pediatrics Pediatrics (weighing ≥ 25 kg): The safety and efficacy in pediatric patients weighing ≥ 25 kg are based on data from an open-label clinical study (see 8 ADVERSE REACTIONS and 14 CLINICAL TRIALS). PM: https://pdf.hres.ca/dpd_pm/00080778.PDF; date July 10, 2018; DIN 02478579; fetched 2026-09-10 Product monograph DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE · General benefit 1 Indications DELSTRIGO® (doravirine/lamivudine/tenofovir disoproxil fumarate) is indicated as a complete regimen for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults and pediatric patients 12 years of age and older and weighing at least 35 kg without past or present evidence of viral resistance to doravirine, lamivudine, or tenofovir. 1.1 Pediatrics Pediatrics ( 12 to < 18 years of age): The safety and efficacy of DELSTRIGO® in pediatric patients 12 years of age and older and weighing at least 35 kg receiving DELSTRIGO® once daily have been established (see 8.2.1 Clinical Trial Adverse Reactions – Pediatrics and 14 Clinical trial). PM: https://pdf.hres.ca/dpd_pm/00081855.PDF; date not captured; DIN 02482592; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS TEVA-ATAZANAVIR (atazanavir capsules) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults and pediatric patients 6 years of age and older weighing at least 20 kg. This indication is based on analyses of plasma HIV-1 RNA levels and CD4 cell counts from controlled studies of 96 weeks duration in antiretroviral-naive patients and 48 weeks duration in antiretroviral-treatment- experienced patients. In antiretroviral-treatment-experienced patients with prior virologic failure, co-administration of TEVA- ATAZANAVIR/ritonavir is recommended (see 14 CLINICAL TRIALS). The number of baseline primary protease inhibitor mutations affects the virologic response to TEVA- ATAZANAVIR/ritonavir (see 15 MICROBIOLOGY - Resistance). (See, 4 DOSAGE AND ADMINISTRATION, 7 WARNINGS AND PRECAUTIONS, 15 MICROBIOLOGY – Resistance.) 1.1 Pediatrics Pediatrics (from 6 to <18 years of age and weighing at least 20 kg): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of atazanavir capsules in pediatric patients have been established. Therefore, Health Canada has authorize… https://pdf.hres.ca/dpd_pm/00078880.PDF PM date: April 18, 2017 Source product: TEVA-ATAZANAVIR; DIN 02443791; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.